Wall Street investors drove Insulet (NSDQ:PODD) shares up nearly 4% today ahead of the insulin management company’s 4th-quarter and full-year earnings statement.

Bedford, Mass.-based Insulet posted losses of $14.3 million, or 30 cents per share, on sales of $47.2 million for the 3 months ended Dec. 31, 2011, adding 70% to the top line and shaving 31.3 percent off of its losses, compared with the same period in 2010.

For the full year Insulet logged losses of $57.2 million, or $1.22 per share, on sales of $152.3 million. That’s a bottom-line improvement of 6.5% and a top-line gain of 57.0%.

Sign up to get our free newsletters delivered straight to your inbox

“We are working closely with the U.S. Food & Drug Administration on the upcoming 510(k) clearance of the next-generation OmniPod. In anticipation, we are in production on the first of our next generation OmniPod manufacturing lines, and we expect the initial international shipments of next generation OmniPods to occur in the coming months,” president & CEO Duane DeSisto said in prepared remarks.”

Insulet said it expects to post sales of $210 million to $225 million this year, with operating losses ranging between $25 million to $35 million.

Guidance For the year ending December 31, 2012, the Company estimates that revenue will be in the range of $210 to $225 million. The Company expects an operating loss of $25 to $35 million for the year ending December 31, 2012. Operating losses for the just-ended year were $42.5 million.

PODD shares closed at $19.88 on Wall Street today, up 3.9%.

 Palomar, Syneron on different post-settlement trajectories

Rival cosmetic device makers Palomar Medical (NSDQ:PMTI) and Syneron (NSDQ:ELOS) are on different trajectories, at least according to their bottom lines, with Palomar swinging to black ink in 2011 and Syneron putting up more red ink for the year.

Palomar posted profits of $7.4 million, or 39 cents per share, on sales of $103.4 million for the year – compared with losses of $8.8 million, or 47 cents per share, on sales of $63.7 million.

For its part, Syneron reported losses of $47.6 million, or $1.35 per share, on sales of $228.3 million in 2011. Although a top-line gain of 20.5% compared with 2010, that’s also 86.4% more losses for the year.

Some of the disparity is due to the $26.0 million Palomar booked from the settlement of a long-running patent war with local rival Candela, which Syneron acquired for $65 million in January 2010. Last September Syneron agreed to pony up $31 million to settle the beef over laser- and light-based hair removal technologies. The company booked $33.9 million in legal settlement costs in 2011.

 Unilife’s Q2 sales slide, losses widen

Second-quarter losses for Unilife (NSDQ:UNIS) widened and sales slid 48.2 percent.

The York, Pa.-based drug delivery device maker posted losses of $12.9 million, or 19 cents per share, on sales of $912,000 during the 3 months ended Dec. 31, 2011.

That compares with losses of $10.4 million, or 19 cents per share, on sales of $1.8 million during the same period in 2010. Read more

 Cardica’s Q2 sales slide, losses widen

Second-quarter losses widened and sales slipped for Cardica (NSDQ:CRDC).

The Redwood City, Calif.-based surgical device maker posted losses of $3.2 million, or 12 cents per share, on sales of $912,000 during the 3 months ended Dec. 31, 2011.

That compares with losses of $3.3 million, or 13 cents per share, on sales of $1.2 million during the same period in 2010. Read more

 Sales, earnings rise for Young Innovations during Q4, 2011

Young Innovations (NSDQ:YDNT) posted sales and earnings increases for the 4th quarter and 2011.

The St. Louis-based dental device maker posted profits of $4.3 million, or 54 cents per share, on sales of $26.7 million during the 3 months ended Dec. 31, 2011.

That compares with profits of $3.8 million, or 47 cents per share, on sales of $25.9 million during the same period in 2010.

For the full year, the company logged profits of $16.5 million, or $2.05, on sales of $106.2 million, compared with profits of $14.9 million, or $1.86 per share, on sales of $102.8 million in 2010. Read more

 Escalon Medical’s Q1 sales dip, losses widen

Losses gapped wider and sales dipped 6.1% for Escalon Medical (NSDQ:ESMC) during its fiscal 1st quarter.

The Wayne, Pa.-based ophthalmology device maker posted losses of $790,000, or 10 cents per share, on sales of $7.0 million during the 3 months ended Sept. 30, 2011.

That compares with losses of $649,000, or 9 cents per share, on sales of $7.5 million during the same period in 2010. Read more